This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Liposomal Bupivacaine for Post-operative Pain Control in Adolescent Bariatric Patients

Sponsored by Virginia Commonwealth University

About this trial

Last updated 2 years ago

Study ID

HM20025041

Status

Recruiting

Type

Interventional

Phase

Phase 1

Placebo

No

Accepting

18-75 Years
13 to 18 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 6 months ago

What is this trial about?

Liposomal bupivacaine (trade name Exparel) is a local analgesic that is designed to produce more long-term pain control. Bupivacaine, a widely used local analgesic, is stored within liposomes, which break down in soft tissue over time. Typical length of therapeutic effect for standard bupivacaine is up to 6 hours. The liposomal formulation of bupivacaine, however, has a length of therapeutic effect of up to 72 hours. Typical post-operative incisional pain is known to last for several days in most cases and is thought to peak between 1-2 days after surgery. Therefore, the benefit of most short-acting local analgesics does not overlap with the period of most need.

What are the participation requirements?

Yes

Inclusion Criteria

- patients who are undergoing a laparoscopic sleeve gastrectomy for severe obesity who are between 13 and 2018 years of age.

- Only patients treated at the Children's Hospital of Richmond at VCU will be included.

No

Exclusion Criteria

- patients less than 13 or greater than 2018 years of age

- patients with an allergy to bupivacaine

- any patients undergoing any additional procedures at the time of the laparoscopic sleeve gastrectomy.

- English or Spanish proficiency will be necessary.

Locations

Location

Status

Recruiting